CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.7% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG (CRSP) is a biotech company specializing in gene editing technologies, particularly using the CRISPR/Cas9 system. Despite its innovative approach to treating genetic disorders, the stock experienced a bearish movement in the market today.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.7% on Apr 24, 2026 18:25

• The stock price of CRISPR Therapeutics (CRSP) dropped by 1.48% during the trading session, closing at $65.80, underperforming the broader market indices like the S&P 500.
• Analysts suggest that the stock may be undervalued based on a Discounted Cash Flow (DCF) model, projecting an intrinsic value significantly higher than the current price.
• Investors are eagerly awaiting positive movement in upcoming earnings reports to potentially reverse the trend of underperformance compared to its peers.
• Despite the company's strategic advancements in gene-based medicines and a positive long-term outlook for its gene-editing portfolio, the stock's movement today reflects market concerns and the need for tangible financial results to drive investor confidence.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?

A Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) is significantly undervalued according to a Discounted Cash Flow (DCF) model, projecting an intrinsic value of $184.14 per share against a current price of $55.18. The article also examines its Price-to-Book ratio, finding it comparable to the biotech industry average, and highlights the use of "Narratives" for personalized valuation perspectives. Overall, the analysis indicates a potential buying opportunity based on future cash flow projections.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) experienced a 0.25% drop in stock price during Tuesday's trading session, closing at $63.09, while the broader market saw gains. The company's performance lagged behind major indices like the S&P 500 and the Nasdaq, continuing a trend of underperformance when compared to its peers over the past month. Investors will be looking for positive movement from upcoming earnings reports to potentially reverse this trend.

https://www.msn.com/en-us/money/topstocks/crispr-therapeutics-ag-crsp-stock-sinks-as-market-gains-what-you-should-know/ar-AA1OoYhz?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t

CRISPR Therapeutics AG (CRSP) stock sinks as market gains: What you should know

CRISPR Therapeutics AG (CRSP) experienced a stock decline of 1.48% on a trading day where the S&P 500 saw gains. The stock closed at $65.80, underperforming the broader market. This movement positions CRSP 17.58% below its 52-week high, although it remains above its 52-week low.

http://www.msn.com/en-us/money/topstocks/crispr-therapeutics-ag-crsp-stock-sinks-as-market-gains-what-you-should-know/ar-AA214qv2?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c

[DEF 14A] CRISPR Therapeutics AG Definitive Proxy Statement

CRISPR Therapeutics AG is convening its 2026 annual general meeting in Zurich on June 4, 2026, to vote on various proposals including the approval of 2025 financial statements, carrying forward a significant accumulated net loss of CHF 1,894,391,436, and re-electing directors. Shareholders will also consider approving compensation for the Board and Executive Committee, increasing the capital band and conditional share capital, and adopting a new 2026 Stock Option and Incentive Plan. The company emphasized its strategic advancements in gene-based medicines, including the first CRISPR-based therapy approval, CASGEVY, in 2023.

https://www.stocktitan.net/sec-filings/CRSP/def-14a-crispr-therapeutics-ag-definitive-proxy-statement-865d0c16974b.html

Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress

Crispr Therapeutics is an emerging gene-editing company developing Crispr/Cas9-based therapeutics for genetically defined diseases. The company's proprietary platform allows precise DNA editing to treat rare disorders. This article highlights the positive long-term outlook for Crispr Therapeutics, with author Rachel Elfman referencing strong uptake for Casgevy and progress in early-stage pipeline assets, including promising Phase 1 data for CTX310.

https://www.morningstar.com/company-reports/1467114-positive-long-term-outlook-for-crispr-therapeutics-as-gene-editing-portfolio-makes-progress

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

CRISPR Therapeutics AG Price History

07.03.2026 - CRSP Stock was down 5.1%

• Despite recent developments on the company's gene-editing therapy, Casgevy, leading to revenue generation and a strong financial position, the stock faced a bearish trend.
• The stock's downturn might be attributed to temporary market fluctuations or profit-taking following a substantial rise in its value in the past year.
• Analysts' varied viewpoints, with Mizuho Securities reconfirming a Buy rating and Piper Sandler also recommending a Buy, could have contributed to the stock's volatility.
• Investors are likely exercising caution ahead of the upcoming earnings release and closely tracking any alterations in forecasts, potentially impacting the stock's short-term performance.

12.02.2026 - CRSP Stock was down 5.1%

• The increase in the convertible notes offering from $350 million to $550 million indicates strong investor demand and a strategic move to bolster financial flexibility for CRISPR Therapeutics.
• Cathie Wood's ARK Invest buying a significant stake in CRSP suggests confidence in the long-term potential of the company despite the bearish market movement.
• The stock's 12% decline following the convertible notes announcement may be attributed to short-term concerns about potential shareholder dilution, although analysts view this as a buying opportunity for investors with a higher risk tolerance.
• Overall, the market reaction seems to be a mix of short-term profit-taking due to fundraising news and long-term optimism about CRISPR Therapeutics' gene-editing platform and drug pipeline.

10.02.2026 - CRSP Stock was down 5.6%

• CRISPR Therapeutics AG (CRSP) is rated as a "Moderate Buy" by Wall Street analysts with a 17% upside potential. Nonetheless, certain AI stocks are viewed as having greater potential with lower risk, potentially drawing investor interest elsewhere.
• Investor attention is increasingly focused on CRSP's valuation, anticipating higher revenue from Casgevy but expressing concerns about significant company losses. The undervaluation potential noted in a discounted cash flow model adds a layer of complexity to the stock's current performance.
• Notable institutional holdings changes include SR One Capital Management LP boosting its stake by 94.4%, while Citigroup Inc. reduced its position by 59.3%. These contrasting actions suggest varying outlooks on CRSP's future.
• ARK Investment Management LLC trimmed its stake in CRSP by 3.9%, yet it remains the 8th largest position in its portfolio. This adjustment, along with other institutional investors and insider selling, likely contributed to today's bearish stock movement.

08.03.2026 - CRSP Stock was up 5.8%

• The recent upward trend in CRISPR Therapeutics' stock price is believed to be linked to the announcement of its senior management team partaking in the 25th Annual Needham Virtual Healthcare Conference. This participation likely boosted investor confidence in the company's future.
• Market enthusiasm towards CRSP is also bolstered by the commercial revenue from its gene-editing therapy, Casgevy, developed in collaboration with Vertex Pharmaceuticals. This revenue stream and the company's strong financial position for upcoming trials indicate potential growth and stability.
• Analysts' assessments, including a Zacks Rank of #3 (Hold), reveal a cautiously optimistic outlook towards CRISPR Therapeutics' performance, with anticipated substantial revenue growth. This positive sentiment could have contributed to the stock's recent bullish movement.

24.03.2026 - CRSP Stock was down 5.6%

• CRISPR Therapeutics AG (CRSP) stock dropped significantly, underperforming the broader market and closing at $63.09.
• The underperformance could be attributed to the company's recent Q4 earnings miss and revenue decline, leading to net selling by company insiders.
• Investors may be cautious due to the company's upcoming annual general meeting, where proposals include carrying forward a significant accumulated net loss and approving compensation for the Board and Executive Committee.
• Despite the bearish movement, the positive long-term outlook for CRISPR Therapeutics, with advancements in gene-based medicines and promising pipeline assets, suggests potential for future growth and recovery in stock performance.

24.03.2026 - CRSP Stock was down 5.7%

• The stock price of CRISPR Therapeutics (CRSP) dropped by 1.48% during the trading session, closing at $65.80, underperforming the broader market indices like the S&P 500.
• Analysts suggest that the stock may be undervalued based on a Discounted Cash Flow (DCF) model, projecting an intrinsic value significantly higher than the current price.
• Investors are eagerly awaiting positive movement in upcoming earnings reports to potentially reverse the trend of underperformance compared to its peers.
• Despite the company's strategic advancements in gene-based medicines and a positive long-term outlook for its gene-editing portfolio, the stock's movement today reflects market concerns and the need for tangible financial results to drive investor confidence.

27.02.2026 - CRSP Stock was down 5.1%

• Truist Financial recently upgraded CRISPR Therapeutics to a "Strong-Buy" rating. However, despite this upgrade, the stock experienced a bearish movement, hinting at other underlying factors impacting its performance.
• Despite some insider selling and recent financial misses, analysts maintain a positive outlook on CRISPR Therapeutics, citing advancements in its pipeline as a driving factor.
• The CEO's reception of significant equity awards and share sales for tax purposes could have influenced the bearish trend, potentially sparking concerns among investors regarding the company's financial stability.
• CRISPR Therapeutics has outperformed the broader market, indicating ongoing investor optimism regarding potential future enhancements in earnings and revenue, notwithstanding recent challenges faced by the company.

13.03.2026 - CRSP Stock was up 5.0%

• CRISPR Therapeutics (CRSP) experienced a strong bullish movement today, likely driven by a combination of factors:
• The company's expansion of its gene-editing pipeline with programs focusing on cardiovascular and metabolic conditions, such as CTX310 and CTX320, has generated positive investor sentiment.
• The forecasted rapid growth of the biomedical CRISPR gene editing market, in which CRISPR Therapeutics is a key player, has likely contributed to the bullish trend.
• Despite facing challenges like significant losses and cash burn, the company's strategic positioning in the gene-editing sector and its participation in high-profile events have boosted investor confidence.
• Analyst valuations and pricing metrics indicating potential undervaluation of CRSP stock have also likely attracted investors seeking growth opportunities in the biotech industry.

14.03.2026 - CRSP Stock was up 5.3%

• Positive investor sentiment and optimism have driven a bullish movement in CRSP's stock today, fueled by recent developments and future prospects.
• The successful launch of Casgevy, generating over $100 million in sales, along with plans to expand the pipeline with six upcoming data readouts in the next 6-12 months, have boosted investor confidence.
• Despite a larger-than-expected quarterly loss, CRISPR Therapeutics' improved cash position, substantial cash reserves of nearly $2 billion, and promising pipeline developments targeting cardiovascular diseases and cancers have attracted investor interest.
• CRISPR's focus on one-time gene edits for conditions related to lipids and metabolic programs like CTX310 and CTX320 presents a compelling long-term investment opportunity, despite challenges such as significant losses and ongoing cash burn, with high execution risk.

31.02.2026 - CRSP Stock was up 5.5%

• CRISPR Therapeutics (CRSP) demonstrated notable bullish movement today, surpassing the broader market performance.
• The positive momentum is linked to an upgrade by Truist Financial to a "Strong-Buy" rating for CRSP. The upgrade highlighted optimism around the company's pipeline, overshadowing recent earnings and revenue setbacks.
• Investors are looking forward to the company's projected year-over-year earnings per share (EPS) and revenue growth, indicating a belief in CRSP's expansion opportunities.
• The market's favorable reception of CRSP's future potential and financial projections reflects investor confidence in the company's innovative gene-editing technology.

17.03.2026 - CRSP Stock was up 5.7%

• Despite recent financial results falling short of expectations, including a larger-than-anticipated quarterly loss and a decline in revenue, CRISPR Therapeutics is capitalizing on the sales growth of its approved therapy, Casgevy, to venture into new areas such as cardiovascular disease, cancers, and autoimmune disorders.
• Analysts are optimistic about the company's potential for future growth, foreseeing substantial revenue growth and major pipeline expansions, including the anticipation of six data readouts in the next 6-12 months.
• The stock's upward trend could be attributed to the excitement surrounding the upcoming clinical program readouts and CRISPR Therapeutics' strategic positioning at the intersection of scientific advancement and commercial strategy, despite some insider selling and mixed analyst outlooks.
• The market's positive reaction to the company's growth strategies and the success of Casgevy in driving sales and establishing treatment centers likely influenced the stock's bullish performance for the day.

11.02.2026 - CRSP Stock was down 5.2%

• CRISPR Therapeutics' stock saw a notable decline of over 12% recently.
• Investor sentiment turned negative following the company's announcement of issuing $350 million in convertible notes to raise capital, raising concerns about potential dilution.
• Analysts, however, remain optimistic about CRSP, seeing the drop as a chance for bold investors to consider buying.
• The decision to issue convertible notes is customary in the biotech field to support research and development initiatives, showcasing CRISPR's dedication to advancing its gene-editing programs despite short-term market reactions.